

**FAX RECEIVED****MORGAN & FINNEGAN, L.L.P.** APR 05 2002

A Registered Limited Liability Partnership

345 PARK AVENUE

NEW YORK, NEW YORK 10154-0053

Tel.: (212) 758-4800

Telex 421792

Facsimile: (212) 751-6849

**GROUP 1600****CONFIDENTIAL**

---

**FAX COVER SHEET**

---

**To:** Supervisory Examiner Gary L. Kunz  
Examiner Sharon L. Turner  
**Company:** USPTO  
**Phone #:** (703) 308-0056  
**Fax #:** (703) 305-3592; 305-3014; 308-4242

**From:** Dorothy R. Auth  
**Phone #:** (212) 415-8564

**Client:** 2026  
**Matter:** 4205

**Date:** April 2, 2002  
**Pages:** 8

**Re:** Serial No. 08/533,895

---

**Comments:**

---

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAINS INFORMATION FROM THE LAW FIRM OF MORGAN & FINNEGAN, L.L.P. WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ON THIS TRANSMISSION SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS FAXED INFORMATION IS STRICTLY PROHIBITED, AND THE DOCUMENT(S) SHOULD BE RETURNED TO THIS FIRM IMMEDIATELY. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE NOTIFY US BY TELEPHONE IMMEDIATELY SO THAT WE CAN ARRANGE FOR THE RETURN OF THE ORIGINAL DOCUMENTS AT NO COST TO YOU.

---

573246 v1

FAX RECEIVED

APR 11 2002

GROUP 1600

PATENT  
Docket No. 2026-4205

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Topalian et al.

Group Art Unit: 1647

Serial No.: 08/533,895

Examiner: Turner, S.

Filed: September 26, 1995

For: MHC CLASS II RESTRICTED MELANOMA ANTIGENS  
AND THEIR USE IN THERAPEUTIC METHODS

Commissioner for Patents  
Washington, DC 20231

**CERTIFICATE OF FACSIMILE TRANSMISSION**


Sir:

I hereby certify that the attached Preliminary Amendment After Withdrawal of  
Finality is being transmitted on the date shown below to the Supervisory Examiner Gary L. Kunz  
and Examiner Sharon L. Turner of Group No. 1647 at the following facsimile number: (703)  
305-3592.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

By:

  
Dorothy R. Auth  
Registration No. 36,434

Dated: April 2, 2002

**Correspondence Address:**

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, NY 10154-0053  
(212) 758-4800 Telephone  
(212) 751-6849 Facsimile

Docket No. 2026-4205**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of : Topalian, et al.  
Serial No. : 08/533,895 Art unit : 1647  
Filed : September 26, 1995 Examiner : Turner, S.  
For : MHC CLASS II RESTRICTED MELANOMA ANTIGENS  
AND THEIR USE IN THERAPEUTIC METHODS

34/#  
MQJ  
4/29/02  
(AB)

**PRELIMINARY AMENDMENT AFTER WITHDRAWAL OF FINALITY****VIA FACSIMILE**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This amendment is provided in response to the Examiner's telephone request for an oral election of invention, i.e., a restriction requirement. The Examiner called the undersigned on March 28, 2002 requesting this election.

**IN THE CLAIMS**

Please amend claims 64-67 and add new claims 94-99.

64. (amended) An isolated Major Histocompatibility Complex Class II immunogenic peptide, wherein said peptide comprises a 9 amino acid segment of a sequence selected from the group consisting of QNILLSNAPLGPF (Ty 56-70) (SEQ ID NO: 1), and NILLSNAPLGPF (Ty 57-70) (SEQ ID NO: 2).